Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXI9BP)

Drug Name
Brilacidin Drug Info
Synonyms
UNII-I1679X069H; 1224095-98-0; I1679X069H; Brilacidin [USAN:INN]; Brilacidin (USAN); SCHEMBL2878543; CHEMBL2219413; DTXSID90153594; AKOS030238222; DB12997; CS-6677; HY-19892; D10414; N,N'-Bis(3-((5-(carbamimidoylamino)pentanoyl)amino)-2-((3R)-pyrrolidin-3-yloxy)-5-(trifluoromethyl)phenyl)pyrimidine-4,6-dicarboxamide; 4,6-Pyrimidinedicarboxamide, N4,N6-bis(3-((5-((aminoiminomethyl)amino)-1-oxopentyl)amino)-2-((3R)-3-pyrrolidinyloxy)-5-(trifluoromethyl)phenyl)-
Indication
Disease Entry ICD 11 Status REF
Acute bacterial skin infection 1C41 Phase 2 [1]
Infectious disease 1A00-CA43.1 Phase 2 [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
Cross-matching ID
PubChem CID
25023695
CAS Number
CAS 1224095-98-0
TTD Drug ID
DMXI9BP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial Cell membrane (Bact CM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [5]
Teicoplanin DMAQ2LK Bacterial infection 1A00-1C4Z Approved [6]
Delamanid DMXE76K Multi-drug resistant tuberculosis MG52.00 Approved [7]
Diphtheria-tetanus vaccine DM0FSIM Clostridium infection 1A04 Approved [8]
D2A21 DMYJ2QB Burn and burn infection ND90-NE2Z Phase 3 [9]
DPK-060 DM059CZ Atopic dermatitis EA80 Phase 2 [10]
LTX-109 DMXEQ0R Bacterial infection 1A00-1C4Z Phase 2 [11]
Friulimicin DMUI8F3 Bacterial infection 1A00-1C4Z Phase 1 [12]
IDR-1018 DM1RNT7 Bacterial infection 1A00-1C4Z Phase 1 [13]
Lotilibcin DMDLTCU Bacterial infection 1A00-1C4Z Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Cell membrane (Bact CM) TTXT4D5 NOUNIPROTAC Enhancer [4]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02324335) Phase 2 Study to Evaluate the Safety & Efficacy of Brilacidin Oral Rinse in Patients With Head and Neck Cancer. U.S. National Institutes of Health.
3 Innovation Pharmaceuticals Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line. June 17, 2020.
4 Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7 Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
8 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
9 In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41.
10 The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29.
11 A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
12 Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60.
13 Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373.
14 Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287.